| Place of Origin: | China |
|---|---|
| Brand Name: | Senwayer Brand |
| Certification: | ISO, 9001, USP |
| Model Number: | 52212-02-9 |
| Minimum Order Quantity: | 10grams |
| Price: | Discount is possible if your order is big enough |
| Packaging Details: | 10g, 20g, 50g , 100g, 500g. 1kg, 10kg |
| Delivery Time: | within 2 working days |
| Payment Terms: | T/T in advance, Money Gram, Western Union, Bank Transfer. |
| Supply Ability: | 1000kg/month |
| CAS: | 52212-02-9 | MF: | C35H62Br2N4O4 |
|---|---|---|---|
| Apparence: | White Crystalline Powder | Purity: | 99% |
| Other Name: | Arduan; PIPECURIUM BROMIDE; Ardtm | Stock: | Ex-stock |
| High Light: | chemical raw material,medical raw material |
||
Injective Pipecuronium Bromide CAS 52212-02-9 Long-acting Muscle Relaxant Drugs
Quick detail
| Pipecuronium Bromide | |
| CAS No.: | 52212-02-9 |
| Synonyms: |
Arduan; PIPECURIUM BROMIDE; Ardtm; PIPECURINIUM BROMIDE; Pipecuronium;Pipecuroniumbromid; pipecuronium bromide;Pipecuriurn Brmnide; RGH-1106; Arduan (tn); |
| Formula: | C35H62Br2N4O4 |
| Exact Mass: | 760.31400 |
| Molecular Weight: | 762.69900 |
| PSA: | 59.08000 |
| LogP: | -2.56510 |
| Appearance : | powder |
| Density: | 1.329 |
| Melting Point: | 262-264ºC |
Pipecuronium Bromide Description
Pipecuronium bromide for injection is a long-acting non-depolarizing neuromuscular blocking agent possessing all of the characteristic pharmacological actions of this class of drugs (curariform). It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine.
Pipecuronium Bromide Usage
Pipecuronium Bromide is a muscle relaxant and an anaesthesia used in patients undergoing coronary artery bypass graft surgery.
Route & Dosage
| 1. Adjunct for General Anesthesia | Adult/Child: IV 85 to 100 mcg/kg, ideal body weight, given as rapid bolus over 5–10 sec or may give over 1 min if desired IV Maintenance Smaller supplemental doses (usually 5–25 mcg/kg) may be given to maintain muscle relaxation during long surgical procedures |
2. Renal Impairment |
Clcr Dose based on ideal body weight: <80 mL/min: 70 mcg/kg; <60 mL/min: 55 mcg/kg; <40 mL/min: 50 mcg/kg |
Pipecuronium Bromide PRECAUTIONS
General
Since ARDUAN® (pipecuronium bromide) for injection has little or no effect on the heart rate, the drug will not counteract the bradycardia produced by many opioid anesthetic agents or vagal stimulation.
| 1. Anaphylaxis |
Since allergic cross-reactivity has been reported in this class, request information from your patients about previous anaphylactic reactions to other neuromuscular blocking agents. In addition, inform your patients that severe anaphylactic reactions to neuromuscular blocking agents, including ARDUAN®, have been reported.
|
| 2. Renal Failure | ARDUAN® in the dose of 70 µg/kg ABW, has been studied in a limited number of patients (n=20) undergoing renal transplant surgery, recently dialyzed in preparation for cadaver renal transplant. The mean clinical duration (injection to 25% recovery) of 103 minutes was not judged prolonged, however, there was wide individual variation (30 to 267 minutes). ARDUAN® has not otherwise been studied in patients with renal failure (for elective or emergency non-renal surgery). Because it is primarily excreted by the kidney, ARDUAN® should be used with caution in patients with renal failure (see Table II, Individualization of Dosage Subsection of CLINICAL PHARMACOLOGY). |
| 3. Increased Volume of Distribution | Conditions associated with an increased volume of distribution, e.g., slower circulation time in cardiovascular disease, old age or edematous states, may be associated with a delay in onset time. Because higher doses of ARDUAN® may produce a longer duration of action, the initial dosage should not usually be increased in these patients to enhance onset time; instead, more time should be allowed for the drug to achieve maximum effect. |
| 4. Hepatic Disease | There are no data on dosage requirements, onset, duration or pharmacokinetics in patients with moderate or severe hepatic dysfunction and/or biliary obstruction. This should be considered in selection of muscle relaxants for use in these patients. |
| 5. Obesity |
The most common patient condition associated with prolonged clinical duration was obesity, defined as 30% or more over ideal body weight (see CLINICAL PHARMACOLOGY). Clinical study subjects were dosed on the basis of actual body weight, which may have contributed to the higher incidence of prolonged duration. It is therefore recommended that dosage be based upon ideal body weight for height in obese patients (see DOSAGE AND ADMINISTRATION).
|
| 6. Malignant Hyperthermia (MH) |
Human malignant hyperthermia has not been reported with the administration of ARDUAN®. Because ARDUAN® is never used alone, and because the occurrence of malignant hyperthermia during anesthesia is possible even in the absence of known triggering agents, clinicians should be familiar with early signs, confirmatory diagnosis and treatment of malignant hyperthermia prior to the start of any anesthetic. In an animal study in MH-susceptible swine (n=7), the administration of ARDUAN® was not associated with the development of malignant hyperthermia.
|
